Aastrom is a regenerative medicine company developing autologous cell products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell (TRC) Technology. Aastrom's TRC-based products are a unique cell mixture of stem and progenitor cells, produced from a small amount of bone marrow taken from the patient. TRC-based products have been used in over 250 patients, and are currently in clinical trials for bone regeneration (osteonecrosis of the femoral head, long bone fractures and spine fusion) and vascular regeneration (critical limb ischemia) applications. Aastrom has reported positive interim clinical trial results suggesting both the clinical safety and the ability of TRC products to promote healing in bone regeneration applications. The Company is also developing programs for TRC-based therapies ...

Contact Information

24 Frank Lloyd Wright Drive
Po Box 376
Ann Arbor, MI 48106

tel: 734-930-5555
fax: 734-665-0485


Investor Relations



Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $52.4M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.